Celldex Therapeutics, Inc. $CLDX Stock Holdings Raised by Vanguard Group Inc.

Key Points

• Vanguard Group Inc. increased its stake in Celldex Therapeutics, owning approximately 5.87% of the company with a total value of $70.76 million as of the last quarter.
• Multiple hedge funds have recently adjusted their positions in Celldex, with GAMMA Investing LLC raising its stake by 6,665.9% during the same period.
• Analyst ratings have varied, with Goldman Sachs lowering its price target from $36 to $31, while other firms maintain positive ratings with a consensus average target price of $46.67.

Vanguard Group Inc. grew its holdings in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 0.4% during the first quarter, according to the company in its most recent disclosure with the SEC. The fund owned 3,898,435 shares of the biopharmaceutical company's stock after buying an additional 16,440 shares during the quarter. Vanguard Group Inc. owned 5.87% of Celldex Therapeutics worth $70,757,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of CLDX. Invesco Ltd. grew its stake in shares of Celldex Therapeutics by 2.1% during the fourth quarter. Invesco Ltd. now owns 42,101 shares of the biopharmaceutical company's stock valued at $1,064,000 after buying an additional 871 shares during the last quarter. Barclays PLC boosted its position in Celldex Therapeutics by 9.6% during the 4th quarter. Barclays PLC now owns 142,914 shares of the biopharmaceutical company's stock valued at $3,611,000 after acquiring an additional 12,533 shares in the last quarter. Guggenheim Capital LLC bought a new stake in Celldex Therapeutics during the 4th quarter valued at $601,000. MetLife Investment Management LLC boosted its position in Celldex Therapeutics by 6.1% during the 4th quarter. MetLife Investment Management LLC now owns 39,620 shares of the biopharmaceutical company's stock valued at $1,001,000 after acquiring an additional 2,288 shares in the last quarter. Finally, Tower Research Capital LLC TRC boosted its position in Celldex Therapeutics by 95.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 20,891 shares of the biopharmaceutical company's stock valued at $528,000 after acquiring an additional 10,185 shares in the last quarter.

Analysts Set New Price Targets

Several analysts have issued reports on CLDX shares. HC Wainwright dropped their target price on Celldex Therapeutics from $50.00 to $42.00 and set a "buy" rating on the stock in a research report on Wednesday, August 20th. Canaccord Genuity Group lowered their price target on Celldex Therapeutics from $64.00 to $62.00 and set a "buy" rating for the company in a research report on Wednesday, August 20th. Wells Fargo & Company reduced their price objective on Celldex Therapeutics from $44.00 to $38.00 and set an "overweight" rating for the company in a research note on Wednesday, August 20th. Citigroup lowered their price objective on Celldex Therapeutics from $56.00 to $48.00 and set a "buy" rating on the stock in a report on Wednesday, August 20th. Finally, The Goldman Sachs Group reduced their price target on shares of Celldex Therapeutics from $36.00 to $31.00 and set a "neutral" rating on the stock in a research report on Friday, May 9th. Seven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $46.67.

Celldex Therapeutics Price Performance

NASDAQ:CLDX traded down $0.30 during trading hours on Friday, reaching $22.08. 1,329,314 shares of the company were exchanged, compared to its average volume of 1,474,976. The stock has a 50 day simple moving average of $22.29 and a 200 day simple moving average of $20.65. Celldex Therapeutics, Inc. has a 52-week low of $14.40 and a 52-week high of $47.00. The firm has a market cap of $1.47 billion, a price-to-earnings ratio of -7.34 and a beta of 1.22.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last issued its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.85) EPS for the quarter, beating analysts' consensus estimates of ($0.86) by $0.01. Celldex Therapeutics had a negative net margin of 3,446.88% and a negative return on equity of 27.61%. The business had revenue of $0.73 million for the quarter, compared to the consensus estimate of $1.13 million. On average, analysts predict that Celldex Therapeutics, Inc. will post -2.48 EPS for the current fiscal year.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.